Bispecific Antibody Market Size

  • Report ID: 5042
  • Published Date: Jun 17, 2023
  • Report Format: PDF, PPT

Bispecific Antibody Market Size

Bispecific Antibody Market size is expected to cross USD 1 Billion by the end of 2035, growing at a CAGR of 7% during the forecast period, i.e., 2023 – 2035. In the year 2022, the industry size of bispecific antibody was around USD 500 Million. The market is primarily driven by a rise in the number of cancer-afflicted people. Simply owing to population increase and aging, the worldwide burden of cancer is anticipated to rise to 27.5 million new cases and 16.3 million cancer deaths by 2040. Bispecific antibodies are a type of immunotherapy that has shown promising results in cancer treatment. Also, it can redirect and activate immune cells to specifically target cancer cells.

Besides this, rising facilities for rare diseases can facilitate access to bispecific antibodies for treatment. On May 4, 2023, the National Organization for Rare Disorders (NORD) unveiled the opening of nine additional Rare Disease Centers of Excellence, bringing the total number of medical facilities of NORD in the United States to 40. Rare diseases are typically associated with unmet medical needs, the establishment of specific facilities will increase the need for antibodies for the treatment of rare diseases.


Bispecific Antibody Market

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5042
  • Published Date: Jun 17, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing prevalence of cancer, a higher instance of autoimmune diseases, and advancement in the bispecific antibody are the major factors driving the market growth.

The market size of bispecific antibody is anticipated to attain a CAGR of ~7% over the forecast period, i.e., 2023 – 2035.

The major players in the market are Innovent Biologics, Ltd., Affimed GmbH, Pieris Pharmaceuticals, Inc., Mereo BioPharma Group plc, TG Therapeutics, Inc., Pfizer Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., and AbbVie, Inc.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drugs, indication, end user, and by region.

The oncology segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Shortage of adequate medical supplies and the high cost of developing the drug is estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying